Bright Minds Announces Proposed Share Consolidation Post published:June 22, 2023 Post category:Press Release
Silo Pharma’s SPU-21 Treatment for Autoimmune Disease Awarded U.S. Patent Post published:June 21, 2023 Post category:Press Release
Delix Therapeutics Announces Completion of 1st Cohort Dosing, Dose Escalation Approval in Phase I Trial for Novel Compound DLX-001 Post published:June 20, 2023 Post category:Press Release
PharmaTher and Vitruvias Enter Into Collaboration Agreement for Commercialization of KETARX™ (racemic ketamine) in the U.S. Post published:June 20, 2023 Post category:Press Release
Clearmind Medicine and SciSparc to Conduct Study Evaluating Combination Treatment for Obesity and Metabolic Syndrome Post published:June 16, 2023 Post category:Press Release
COMPASS Pathways to participate in upcoming Cantor Fitzgerald and HC Wainwright investor conferences Post published:June 16, 2023 Post category:Press Release
Optimi Health To Supply MDMA For Therapist Experiential Training Program at Numinus, Supported by MAPS Post published:June 15, 2023 Post category:Press Release
Numinus Announces Partnership with MAPS to Support Therapist Psychedelic Experiential Training Post published:June 15, 2023 Post category:Press Release
Numinus Appoints New Chief Financial Officer Post published:June 14, 2023 Post category:Press Release
Silo Pharma Signs Agreement to Develop First-in-Class Ketamine Implant Therapeutic Post published:June 13, 2023 Post category:Press Release